Publication: RBE variation in prostate carcinoma cells in active scanning proton beams: In-vitro measurements in comparison with phenomenological models
Issued Date
2020-09-01
Resource Type
ISSN
1724191X
11201797
11201797
Other identifier(s)
2-s2.0-85090054600
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Physica Medica. Vol.77, (2020), 187-193
Suggested Citation
Suphalak Khachonkham, Elisabeth Mara, Sylvia Gruber, Rafael Preuer, Peter Kuess, Wolfgang Dörr, Dietmar Georg, Monika Clausen RBE variation in prostate carcinoma cells in active scanning proton beams: In-vitro measurements in comparison with phenomenological models. Physica Medica. Vol.77, (2020), 187-193. doi:10.1016/j.ejmp.2020.08.012 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/58966
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
RBE variation in prostate carcinoma cells in active scanning proton beams: In-vitro measurements in comparison with phenomenological models
Abstract
© 2020 Associazione Italiana di Fisica Medica Purpose: In-vitro radiobiological studies are essential for modelling the relative biological effectiveness (RBE) in proton therapy. The purpose of this study was to experimentally determine the RBE values in proton beams along the beam path for human prostate carcinoma cells (Du-145). RBE-dose and RBE-LETd (dose-averaged linear energy transfer) dependencies were investigated and three phenomenological RBE models, i.e. McNamara, Rørvik and Wilkens were benchmarked for this cell line. Methods: Cells were placed at multiple positions along the beam path, employing an in-house developed solid phantom. The experimental setup reflected the clinical prostate treatment scenario in terms of field size, depth, and required proton energies (127.2–180.1 MeV) and the physical doses from 0.5 to 6 Gy were delivered. The reference irradiation was performed with 200 kV X-ray beams. Respective (α/β) values were determined using the linear quadratic model and LETd was derived from the treatment planning system at the exact location of cells. Results and Conclusion: Independent of the cell survival level, all experimental RBE values were consistently higher in the target than the generic clinical RBE value of 1.1; with the lowest RBE value of 1.28 obtained at the beginning of the SOBP. A systematic RBE decrease with increasing dose was observed for the investigated dose range. The RBE values from all three applied models were considerably smaller than the experimental values. A clear increase of experimental RBE values with LETd parameter suggests that proton LET must be taken into consideration for this low (α/β) tissue.